Primary liver cancer
Conditions
Interventions
D-TACE group:D-TACE
c-TACE group:c-TACE
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years, gender is not limited; 2. Primary liver cancer diagnosed by histopathology or clinical diagnosis (refer to Primary Liver Cancer Diagnosis and Treatment Standards (2019 Edition) issued by the Ministry of Health of China), and no other anti-tumor therapy before surgery; 3. Clinically diagnosed as unresectable liver cancer, or patients with liver cancer who are unable or unwilling to undergo surgical resection due to other reasons (such as advanced age, severe liver cirrhosis, etc.), and patients who plan to undergo hepatic arterial chemoembolization; 4. Liver function Child-Pugh grade A or better B (= 3.0x10^9/L, hemoglobin >= 8.5g/dl, platelet count >= 50 x 10^9/L, INR <= 2.3 or PT prolongation <= 3 seconds , serum creatinine < 1.5 times the upper limit of normal; 8. Patients voluntarily joined the study and signed an informed consent form (ICF); 9. Those who are expected to have good compliance can follow up the curative effect and adverse reactions according to the program requirements.
Exclusion criteria
Exclusion criteria: 1. There are obvious contraindications for interventional treatment: such as obvious arterial/venous fistula; uncorrectable coagulation dysfunction and obvious abnormal blood picture, with obvious bleeding tendency; refractory massive ascites; 2. Complicated with active infection, especially inflammation of the bile duct system; 3. There is tumor thrombus in the main portal vein, or there are more collateral vessels to compensate for portal vein blockage; 4. Serious heart, lung, kidney, and brain and other important organ diseases; 5. Those who have suffered or are currently complicated by other malignant tumors (except for cured basal or squamous cell skin cancer); 6. History of allergy to iodine, chemotherapy or other related drugs; 7. Pregnant or lactating patients; 8. Patients with a history of previous interventional therapy for liver cancer; 9. Other patients who are considered unsuitable for inclusion by the treating physician.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Serious Adverse Events; | — |
Countries
China
Contacts
Public ContactLiu Fangfeng
Shandong Provincial Hospital
Outcome results
None listed